Webinar for the X-Linked Retinitis Pigmentosa (XLRP) Community

You Are Invited To Attend a Virtual Webinar for The X-Linked Retinitis Pigmentosa (XLRP) Community On Friday, April 22nd From 3:00-4:00 P.M. ET

The purpose of this webinar is to provide details about an upcoming Externally-Led Patient Focused Drug Development (EL-PFDD) meeting for XLRP, and to provide background information about the Food and Drug Administration’s (FDA) drug review process. 

The EL-PFDD meeting will be held virtually on June 7th, 2022, from 10:00 a.m. to 3:00 p.m. Eastern Time. The goal of the June 7th meeting is to educate FDA staff and other key stakeholders such as biotech and pharmaceutical companies about what it is like to live with XLRP, with perspectives from both affected individuals as well as caregivers and family members of affected individuals. The FDA staff can use this information when reviewing new clinical trials or new drug applications for XLRP. 

EL-PFDD meetings are unique among public meetings with the FDA and other stakeholders, with a format designed to engage patients and elicit their perspectives on two topic areas: 
(1) the most significant symptoms of their condition and the impact of the condition on daily life; and 
(2) current approaches to management or treatment.

Please join us on April 22nd to learn about this important meeting for our community and how you can be involved. Your input is an invaluable resource to ensuring that this meeting is successful, and we would appreciate as many people in attendance as possible. We look forward to meeting with you!

To participate by Zoom, please click below:

Join Zoom Meeting

To participate by telephone, simply dial:

+1 301 715 8592 US (Washington DC)
+1 312 626 6799 US (Chicago)
+1 646 558 8656 US (New York)
+1 253 215 8782 US (Tacoma)
+1 346 248 7799 US (Houston)
+1 669 900 9128 US (San Jose)
888 475 4499 US Toll-free
877 853 5257 US Toll-free
Or find your local number here

Meeting ID: 836 6450 8695

Passcode: 073353